ckd patients with type 2 diabetes mellitus

patients whose egfr levels are eligible for this study

patients being treated with stable dose of ace inhibitors and/or arb etc.

patients with type 1 diabetes

patients with known non-diabetic renal disease

patients with a history of renal transplantation

patients with mean sbp > 160 mmhg or mean dbp > 90 mmhg

patients with hba1c > 10%

patients with cardiovascular disease specified in the study protocol

patients for whom inulead® injection is contraindicated etc.